UK-based T-Therapeutics secured $133 million to support its T cell receptor (TCR) programs in autoimmune disease and oncology. The funding brings in Johnson & Johnson, Merck KGaA, and Eli Lilly, joining Sanofi as backers, reflecting continued large-pharma appetite for engineered immune-recognition platforms. The company’s focus on TCR modalities targets both disease-specific immune control and therapeutic expansion opportunities where conventional antigen approaches have struggled. For investors and partners, the key takeaway is momentum behind next-generation cell-sensing formats that can translate into multiple indications. While specific clinical milestones weren’t detailed in the provided brief, the deal size signals confidence that TCR candidates can move through translational stages with scalable development plans.